RT Journal Article
T1 Molecular Basis of CYP19A1 Deficiency in a 46,XX Patient With R550W Mutation in POR: Expanding the PORD Phenotype.
A1 Parween, Shaheena
A1 Fernández-Cancio, Mónica
A1 Benito-Sanz, Sara
A1 Camats, Núria
A1 Rojas Velazquez, Maria Natalia
A1 López-Siguero, Juan-Pedro
A1 Udhane, Sameer S
A1 Kagawa, Norio
A1 Flück, Christa E
A1 Audí, Laura
A1 Pandey, Amit V
K1 CY19A1
K1 CYP17A1
K1 CYP21A2
K1 POR
K1 PORD
K1 congenital adrenal hyperplasia
AB Mutations in cytochrome P450 oxidoreductase (POR) cause a form of congenital adrenal hyperplasia (CAH). We report a novel R550W mutation in POR identified in a 46,XX patient with signs of aromatase deficiency. Analysis of aromatase deficiency from the R550W mutation in POR. Both the child and the mother had signs of virilization. Ultrasound revealed the presence of uterus and ovaries. No defects in CYP19A1 were found, but further analysis with a targeted Disorders of Sexual Development NGS panel (DSDSeq.V1, 111 genes) on a NextSeq (Illumina) platform in Madrid and Barcelona, Spain, revealed compound heterozygous mutations c.73_74delCT/p.L25FfsTer93 and c.1648C > T/p.R550W in POR. Wild-type and R550W POR were produced as recombinant proteins and tested with multiple cytochrome P450 enzymes at University Children's Hospital, Bern, Switzerland. POR-R550W showed 41% of the WT activity in cytochrome c and 7.7% activity for reduction of MTT. Assays of CYP19A1 showed a severe loss of activity, and CYP17A1 as well as CYP21A2 activities were also lost by more than 95%. Loss of CYP2C9, CYP2C19, and CYP3A4 activities was observed for the R550W-POR. Predicted adverse effect on aromatase activity as well as a reduction in binding of NADPH was confirmed. Pathological effects due to POR-R550W were identified, expanding the knowledge of molecular pathways associated with aromatase deficiency. Screening of the POR gene may provide a diagnosis in CAH without defects in genes for steroid metabolizing enzymes.
YR 2020
FD 2020
LK http://hdl.handle.net/10668/15112
UL http://hdl.handle.net/10668/15112
LA en
DS RISalud
RD Apr 6, 2025